Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma
Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine
Efficacy
Median OS: 21.7 vs. 16.0 months (HR: 0.51 [95% Cl, 0.37-0.71])
Median PFS: 3.3 vs. 2.9 months (HR: 0.73 [95% Cl, 0.58-0.94])
1-year OS: 73% vs. 59% (HR: 0.51 [0.37-0.71] P<0.001)
6 months PFS: 31% vs. 19% (HR: 0.73 [0.58-0.94], P=0.01)
Safety
Any grade AEs: cytokine release syndrome (89% vs. 3%), rash (83% vs. 24), pyrexia (76% vs. 3%), pruritus (69% vs. 21%), chills (47% vs. 3%), nausea (43% vs. 19%), fatigue (41% vs.26%), hypotension (38% vs 0%)
